Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

Serial bloodstream isolates from two critically ill London patients showed heteroresistance, CRZ1 escape mutations, and drug-induced polyploidy despite wild-type FKS1 and susceptible MICs.

Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.

Detection of the virulent neurotropic fungus Cladophialophora bantiana in clinical samples, primarily CNS tissue, increased four-fold in the period from 2023 to 2025.

UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.